Tagraxofusp

Tax included
Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM).
MedChemExpress 
HY-P99536

Data sheet

Size
Multiple sizes
Reactivity
Interleukin Related
Application
Cancer-programmed cell death
CAS
2055491-00-2